EGAGenomicsWhole Genome Sequencinghttps://ega-archive.org/studies/EGAS00001007066EGAEGA study EGAS00001007066Whole genome sequencing data of paediatric ETV6-RUNX1 acute lymphoblastic leukemiaEGArestrictedRunx-1, treatment, Therapy, aml, leukemia, reactivity, Pebp2a2, AML1-EVI-1, Leucocythemia, CBF-alpha-2, AMLCR1, Xaml1, Aml1, AML1, Leucocythemias, AW123102, CBFA2, amlcr1, Treatments, pebp2ab, aml1, Leukemias, XAML, Cbfa2, EVI-1, PEBP2aB, Therapeutic, Pebpa2b, responsivity, aml-1, disease management, Therapies, leukaemia NOS, Treatment, Leucocythaemias., AI462102, response, Leucocythaemia, aml1-evi-1, TEL|ABL, AW557856, TEL/ABL, cbfa2, leukaemia, TEL, Tel, evi-1Forms, B Cells, precursor lymphoblastic lymphoma/leukemia, Lymphocytic Leukemia, HSN1E, Bursa-Dependent Lymphocytes, Feature, chemotherapy, B cell, B acute lymphoblastic leukaemia, acute lymphoblastic leukaemia, pharmacotherapy, Prognostic Factors, Pharmacotherapies, B-cell lymphoblastic leukemia, B-cell lymphoblastic leukaemia, Chemotherapies, Relative, Aim, method, relapse, AIM, Cbfa2, B-cell type acute leukaemia, method used in an experiment, PUJO, slow, Low, Relapses, increase in risk, Childhood ALL, Drug Therapies, MRD, Runx-1, Lymphocytic, treatment, DNMT1, study, reactivity, Pebp2a2, B-cell, me75, Leukemia, B-cell acute lymphoblastic leukaemia, Prognoses, lymphoblastic leukaemia, AMLCR1, DNMT1_HUMAN, acute B-cell lymphocytic leukemia, Recrudescences, Recurrences, Adult, amlcr1, pebp2ab, aml1, D17Mit170, B-cell acute lymphocytic leukemia, T1, B-cell acute lymphoblastic leukemia, XAML, genetic, API6, L2 Lymphocytic, Acute Lymphoblastic, high frequency, L1, lymphoblastic leukemia, L2, L1 Lymphocytic, B lymphocyte, Pebpa2b, Precursor Cell Lymphoblastic Leukemia Lymphoma, Clients, disease management, Therapies, s, Acute lymphoblastic leukemia, Lymphoid, B cell acute lymphocytic leukaemia, Characteristics, TEL|ABL, AW557856, constitutitional genetic, CXXC finger protein 9, B-cell acute lymphocytic leukaemia, DNA MTase HsaI, DNA (cytosine-5)-methyltransferase 1, ALL, Therapy, Relapse, CBF-alpha-2, B cell acute lymphocytic leukemia, B acute lymphoblastic leukemia, cou, B Lymphocytes, Aml1, acute B cell lymphocytic leukaemia, AML1, DNMT, familial, B-cell type acute leukemia, responsivity., Lymphoid Leukemia, Philadelphia-Positive, Factor, MCMT, Tl3, Tl2, L1 Lymphocytic Leukemia, Client, Lymphoblastic Lymphoma, Pelvi-ureteric junction obstruction, Lr, Characteristic, EVI-1, PEBP2aB, Acute Lymphoid Leukemia, Recrudescence, DNA methyltransferase HsaI, Relative Risks, Acute Lymphocytic, Chemotherapy, AI462102, Acute Lymphoid, aml1-evi-1, TEL/ABL, cbfa2, acute lymphocytic leukaemia, evi-1, Relative Risk, Lymphoblastic Leukemia, slow speed, CXXC9, aml, B-ALL, acute B-cell lymphocytic leukaemia, ADCADN, AML1-EVI-1, Factors, frequent, Pharmacotherapy, Risk, UNQ203/PRO229, CT-2, Xaml1, Prognostic, DNA (cytosine-5-)-methyltransferase 1, Risks, Lymphoblastic, Bursa-Equivalent Lymphocyte, AW123102, CBFA2, Childhood, Acute Lymphoblastic Leukemia, Features, study protocol, Treatments, CXXC-type zinc finger protein 9, Drug, plan specification, Acute, Patient, Therapeutic, B-Lymphocyte, Lymphoma, aml-1, Bra, L2 Lymphocytic Leukemia, Treatment, pharmacologic therapy, inherited genetic, response, acute B cell lymphocytic leukemia, B-lymphocyte, TEL, Tel, hereditary, Acute Lymphocytic Leukemia, CLEC2C, m.HsaI, Prognostic FactorfalseGenomic determinants of therapy response in ETV6-RUNX1 leukemiaETV6-RUNX1 (E::R) subgroup is the second most frequent form of B cell acute lymphoblastic leukemia (B-ALL) in childhood. This subgroup of ALL generally presents with low-risk features and responds well to chemotherapy with ensuing favorable prognosis. Some patients, however, have a slow response to induction treatment and carry increased risk for relapse. The aim of this study is to identify genetic differences between E::R cases stratified by MRD (NOPHO ALL2008 protocol), and to identify potential mediators of poor therapy response.2023-04-17 11:07:58EGAS000010070669606EGAD00001010128EGAC00001003137